Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9311601 | 0.80 | TSHR (0.48) | TSHRMEN1KMT2ANOS1NOS2 | |
| SCHEMBL3479436 | 0.79 | CA1 (0.35) | TAAR1 | |
| SCHEMBL225197 | 0.78 | TSHR (0.54) | TSHRMEN1KMT2ANOS1NOS2 | |
| SCHEMBL13064226 | 0.77 | TSHR (0.42) | TSHRMEN1KMT2ATAAR1 | |
| SCHEMBL8733207 | 0.76 | TP53 (0.48) | TSHRLMNA | |
| SCHEMBL28326229 | 0.76 | TSHR (0.45) | TSHRMEN1KMT2ANOS1NOS2 | |
| SCHEMBL33722031 | 0.76 | TSHR (0.45) | TSHRMEN1KMT2ANOS1NOS2 | |
| SCHEMBL9454763 | 0.74 | MAOA (0.56) | TSHRMEN1KMT2ATAAR1 | |
| SCHEMBL23794950 | 0.73 | LPL (0.49) | — | |
| SCHEMBL30861915 | 0.73 | LPL (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825103-B2 | 5'-O-triisopropylsilyl-2'-cyano-2'-deoxy-1- beta -D-arabinofuranosylcytosine; antitumor agents | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1845102-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | CDK10, SRSF9, SNRPD1 | TSHR 2261/4885MEN1 2140/4885KMT2A 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.